# Non-inferiority Study of ZK-A03 in Treatment of Herpes Zoster Before and After the Alteration of the Active Ingredient Manufacturer

> **NCT05806918** · PHASE3 · UNKNOWN · sponsor: **Lee's Pharmaceutical Limited** · enrollment: 368 (estimated)

## Conditions studied

- Herpes Zoster

## Interventions

- **DRUG:** Recombinant Human Interferon α-2b Gel (After the Alteration)
- **DRUG:** Recombinant Human Interferon α-2b Gel (Before the Alteration)

## Key facts

- **NCT ID:** NCT05806918
- **Lead sponsor:** Lee's Pharmaceutical Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-01
- **Primary completion:** 2023-07-30
- **Final completion:** 2023-08-30
- **Target enrollment:** 368 (ESTIMATED)
- **Last updated:** 2023-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05806918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05806918, "Non-inferiority Study of ZK-A03 in Treatment of Herpes Zoster Before and After the Alteration of the Active Ingredient Manufacturer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05806918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*